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Abstract
THE EFFECTS OF A PROTEIN SPARING MODIFIED FAST
ON INSULIN AND GLUCAGON LEVELS
by Elizabeth Anne Shirley
A total of 18 obese men and women volunteered and participated
in a seven-day protein sparing modified fast providing A00 calories per
day. The subjects were concurrently participating in an eight-week
weight control program combining the facets of nutrition education,
group therapy, and values clarification. The modified fast, which was 
optional, was conducted during two different time periods with a con­
ventional low calorie diet prescribed during the four-week interval.
The diet formula consisted of a high biological value protein,
dried egg white, and either glucose or corn starch as the carbohydrate
source. The composition of the diets varied as follows: Diet I - 75 
% protein, 25% corn starch; Diet II - 75% protein, 25% glucose; Diet 
III - 25% protein, 75% corn starch; Diet IV - 25% protein, 75% glucose. 
The hormonal response of glucagon and insulin relative to the four
diets was evaluated. Baseline and post-fast serum samples were ob­
tained from the subjects.
Analysis showed no significant difference in response elicited 
by the various diets of either insulin or glucagon or in the insulin 
to g1ucagon ratio. The mean weight loss during both modified fasting
periods was 7-5 pounds with a range of one pound to 16 pounds. The
total weight loss for an individual at the end of the eight-week 
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INTRODUCTION
Health professionals agree that obesity is a hazard to health
and a detriment to well-being. But for most individuals, this major
health problem cannot be categorized solely as a nutritional, medical
or psychological condition. Social, economic and educational forces
are involved in establishing lifestyle habits and patterns of eating
and physical activity. Thus, obesity is not only a problem of the
individual but of society as well.
The complications of obesity (1) include: accelerated arterio­
sclerotic cardiovascular disease, hypertension, diabetes mellitus,
hyperlipidemia, gallbladder disease and endocrine related neoplasms.
Obesity also appears to hasten the degenerative disease of the aging.
Treatment of the obese individual includes the use of diet
pills (2), formula diets (3), hypnosis (4), injections (5), behavior 
modification (6), short-term or prolonged fasting (7), jejunoileal 
(8), or gastric bypass surgery (9), and group therapy (10). 
success of any one method is often limited and therefore the problem 
usually requires a more comprehensive approach (11).
The facets of nutrition education, group therapy, values 
clarification and the option of participating in the protein-sparing
But the
modified fast (hereafter PSMF) were combined into an eight-week
summer program designed to encourage weight loss and positive behavior
change, as well as to establish healthful eating patterns. The PSMF
was included in this program since it is designed to induce the selec­




The effects of two weight loss regimens--tota1 starvation and 
the PSMF--Wi11 be compared as well as the different physiological and 
clinical changes observed with the hypocaloric intake of carbohydrate,
More specifically, the hormonal response of glucagon 




Physiological Effects of Starvation
Total fasting was first recommended as an effective treatment
for obesity by Folin and Dennis in 1915 (12). Cahill has reviewed the
metabolic adaptations that occur during fasting (13). Stage 1 of
starvation is characterized by the depletion of glucose stored in the
form of glycogen in the liver. In adult man the liver stores approxi­
mately 100 gms of glycogen, which will supply the brain's requirement 
for glucose for several hours (14).
During the second stage of fasting the body's fuel system is
converted to gluconeogenesis, utilizing amino acids from muscle protein 
and creating a negative nitrogen balance (15). 
of 60 percent (16), serves as a primary gluconeogenic precursor (17), 
and its conversion to glucose appears to be enhanced by glucagon (18). 
Significant rises of the glycogenic amino acids--threonine, serine, gly­
cine, alphaaminobutyrate, methionine, tyrosine and lysine—contrast 
with the reduction in amino acids released during prolonged starvation
Alanine, with increases
(19).
After the initiation of starvation, the loss of body weight 
usually is greater than can be ascribed to negative caloric balance.
The excessive losses of fluid and sodium have been attributed to the
increased serum glucagon levels (20). There is a significant increase
in nitrogen loss from day one to day three followed by a steady 
decrease (21). The breakdown and loss of lean body mass--approximately 
60 to 75 gm per day (22)--is later conserved as adipose stores begin
3
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to meet energy needs (23).
The rise in glucagon at this time ensures that an acceptable 
level of blood glucose is maintained by means of two mechanisms: 
release of glucose from liver glycogen, and 2) as fasting is prolonged, 
causing the liver to synthesize glucose from the glycogenic amino acids 
which thereby decreases their concentration in the bloodstream (24).
In prolonged starvation, Stage III, the body begins to adapt 
to the fasting state with a gradual shift to almost entirely fat based
1)
fuel (25). Ketone bodies gradually replace glucose as fuel for the 
brain (26) and minimize g1uconeogenesis (27). The liver recycles lac­
tate derived from fatty acid oxidation and the net result is conserva­
tion of body protein (28). Total fasting, when fully effective after
about three weeks, results in a daily loss of approximately 0.3 kg fat
and 0.1 kg lean tissue in men or 0.2 kg fat and 0.1 kg lean tissue in 
women (29). At equal weight, greater nitrogen loss occurs in men than
in women, both normal and obese (30). Nitrogen loss is also lower in
obese patients than normal weight subjects (31). This is probably a
result of increased lipolysis and accelerated hepatic ketogenesis due 
to the excess body fat content of obesity. Therefore, the ratio of 
nitrogen loss to weight loss during an extended fast is inversely 
related to body fat content (32).
In one study obese mice retained an average of only 3*3 per­
cent of the nitrogen consumed whereas lean mice retained 5.2 percent. 
Additionally, the site of deposition varied--obese mice retained only 
35 percent of their nitrogen in the carcass (skeletal muscle and 
skeleton) while lean mice retained 58 percent of their nitrogen in
5
This was associated with a proportionate increase inthe carcass.
nitrogen retention in adipose tissue of obese mice who retained 17 per­
cent of their nitrogen in adipose itssue whereas lean mice did not
accumulate additional nitrogen in their adipose tissue. This is
consistent with the accelerated fractional turnover of skeletal muscle
in obese mice (33)•
Besides the great amount of lean body mass catabolized during
starvation, prolonged fasting causes many other undesirable effects
including alterations in liver (3^), renal (35) and endocrine func­
tion (36) and a decrease in blood volume (37)-
(38) is accompanied by an excessive excretion of the
Reduced absorption
of vitamin B 12
B-complex vitamins (39). There may also be an increased need for
pyridoxine (40), folic acid (^1), riboflavin and especially thiamine
m. Anemia is sometimes evidenced in patients after prolonged
fasting and is associated with a fall in serum protein, RBC count
and hemoglobin (43). Magnesium (44), calcium (45) and phosphate (46)
are lost in gradually diminishing amounts. Hyponatremia (47) with a
hypotonic dehydration may be responsible for nausea, fatigue, apathy, 
dizziness and orthostatic hypotension (48). Hyperuricemia is due
mainly to an impairment of renal clearance (49) or to the competition 
of urates with ketones for a common tubular site (50). Decreased
cholesterol and triglyceride production in prolonged fasting occurs 
in the presence of elevated FFA and blood ketones (51). 
concentrations of triiodothyronine (T3) (52) and the ketosteroids (53) 
also occurs.
Reduced
Ketone body levels are maximal at three weeks as muscle
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tissue adapts to fatty acid utilization (5^). Sherwin et al. (55) have
shown that infusions of ketones improve nitrogen balance of human sub­
jects and produce a marked fall in serum alanine. The branched chain
amino acids (BCAA) and their ketoanalogues, which are important in
slowing the rate of skeletal protein breakdown and improving the status 
of protein synthesis (56), are also spared from oxidation in extra- 
hepatic sites by ketone bodies (57)•
The Ketogenic Response and Its Regulation
Hepatic fatty acid oxidation and ketone body production has 
been reviewed by McGarry (58). The primary site of ketogenesis is the
liver where acetyl CoA undergoes reactions to form acetoacetate and
3-hydroxybutyrate. Malonyl CoA, identified as the control point in
the ketotic system, is concentrated in the liver, and tissue levels
fluctuate with the rate of fatty acid synthesis (see Figure 1). I ts
inhibitory site is carnitine acyl transferase I (CAT l), which acts
as the auxiliary control and catalyzes the transfer of long-chain 
fatty acid across the mitochrondrial membrane (see Figure 2). Glucagon 
and insulin induce the biochemical changes in the regulation of keto­
genesis, and it appears that the hormonal ratio is more important than 
the absolute concentrations of either hormone (see Figure 3). The 
ketogenic action of glucagon primarily results in: 1) the stimulation 
of B-oxidation by the removal of the malonyl CoA blockage on CAT I, 
and 2) the inhibition of glycolysis.
The ketotic state exhibits an elevation of the glucagon to






















Figure 1. Regulatory interactions between the pathways of fatty 
acid synthesis and oxidation in liver. In the fed state malonyl- 
CoA levels are high, assuring rapid fatty acid synthesis and 
suppression of fatty acid oxidation (through inhibition of car­
nitine acyl transferase 1). Malonyl-CoA concentrations may be 
lowered by glucagon excess or high tissue levels of fatty acyl- 
CoA. In both cases the net result is cessation of lipogenesis 






Fatty acyl-CoA Fatty acyl - 
Carnitine
Fatty acyl-CoA







etc. Krebs cycle HMG-CoA cycle
VV
Ketone bodiesco2
Figure 2. Major disposal routes of long chain fatty acids in liver. 
CAT I and CAT II refer to carnitine acyl transferase I and II, respec­
tively.
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Figure 3- Bihormonal model for the control of ketogenesis. 
The model proposes that the mobilization of free fatty acids 
(FFA) from adipose tissue to liver results primarily from 
insulin deficiency. The activation of hepatic fatty acid 
oxidation and ketogenesis comes about through elevation of 
the [glucagon] : [insulin] ratio.
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Consequently, lipogenesis is inhibited and the augmentation of fatty
acid oxidation and ketogenesis occurs at high uninhibited rates.
Intrahepatic concentrations of long chain acyl-CoA, the substrate
for CAT I, rise. The increase in hepatic carnitine and fatty acyl-CoA
enhances beta oxidation and increases the production of acetoacetate
and 3“hydroxybutyrate.
Conversely, the carbohydrate fed condition results in low
glucagon to insulin ratio, and fatty acid metabolism moves toward
synthesis with a blockage of oxidation. The characteristic high tis­
sue levels of malonyl CoA inhibit CAT I.
McGarry has shown that the higher the rate of hepatic ketogene-
sis, the less the proportion of any available FFA that will be esteri-
fied to triglyceride (59). When isolated livers are exposed to
increasing concentrations of glucagon, ketogenesis increases and tri­
glyceride production decreases (60).
The Behavior of Insulin in the Obese Individual
Obesity is a well-known condition that leads to the develop­
ment of insulin resistance (6l). Since the great majority of adult.
Type II diabetic patients are overweight, obesity-induced insulin
resistance is often a contributing factor in the hyperglycemia of 
Olefsky (62) has reviewed this topic.these patients.
Insulin is produced in the pancreatic beta cell as the
biosynthetic product pre-proinsulin. After conversion to insulin
(MW 6000) plus C-peptide (MW 3000) by specific proteolytic steps
within the beta cell secretory granule, the hormone interacts with
11
target tissues to exert its biologic effects. Insulin's major role is
to promote overall glucose metabolism, and abnormalities of this
aspect of insulin action can lead to a number of important clinical
and pathologic states. When a given quantity of insulin exerts less
than the normal expected biologic effect, then insulin resistance is
said to exist.
In the obese individual or type II diabetic the cause of
insulin resistance resides at the level of the target tissue. Wi th
mild insulin resistance the impairment in insulin action is due to
decreased numbers of cellular insulin receptors leading to decreased
insulin sensitivity. In patients with severe insulin resistance,
decreased insulin receptors and a post-receptor defect in insulin
action co-exist, but the post-receptor defect is the predominant ab-
norma1ity.
Hyperinsulinemia favors the uptake of glucose and trigly­
cerides by body fat while inhibiting fat mobilization (63). This is
an undesirable metabolic situation for the obese individual. With
increased fat mass and resulting increased free fatty acid turnover, 
further hyperinsulinemia occurs. It follows that weight-reducing
regimens should be specifically designed to allow a sharp fall in
insulin 1evels.
Rats subjected to starvation for 72 hours showed a decrease
in plasma insulin which was also associated with a block in peptide-
chain initiation, a subsequent loss of protein synthetic capacity
and a decrease in muscle RNA. Perfusion of muscle with insulin
12
removed the block in peptide chain initiation, restoring the effi­
ciency of protein synthesis to normal (64). When starved rats are
killed 30 minutes after a single injection of insulin (0.8 units, 
subcutaneously) there is a twofold increase in protein synthetic 
activity of the fat cell ribosomes which indicates insulin action at
the level of peptide chain initiation (65).
The role played, however, by specific nutrients in the hyper-
insulinemia of obese individuals has not been clearly defined and
there is much contradictory evidence. Studies by Grey and Kipnis 
(66) suggest that diets high in CHO are associated with hyperinsuli-
nemia while isocaloric diets low in CHO decrease circulating insulin 
Alternatively, Brunzell et a 1. (67) reported that high CHO 
diets given to normal subjects or mildly diabetic patients decrease
1evels.
basal and glucose stimulated insulin levels and improved glucose
tolerance. In contrast, the amino acids, arginine, lysine, leucine
and threonine, have been identified as potent insulin secretagogues 
(68) and Schteingart (69) implies that protein restricted diets will
decrease basal plasma insulin levels.
Landau et_ aj_. (70) compared nitrogen metabolism and insulin 
secretion during a two-day total fast and a modified fast (1.5 gm 
protein/kg body weight). A negative nitrogen balance and a drop in
insulin levels to 13“22 percent of control base-line data was seen
during fasting. With the modified fast nitrogen equilibrium was
approached but insulin values were identical to those observed with
fasting. The authors concluded that the protein-sparing influence
13
of protein feeding cannot be ascribed to the decline in insulin
secretion.
The Role of Glucagon
In 1923 Murlin et al. (71) discovered a hyperglycemic factor
in crude insulin preparations from canine pancreas. This substance
he called glucagon. Glucagon is a single chain peptide containing
29 amino acid residues, with a molecular weight of 3^85. It is
synthesized in the A-cells of the pancreatic islets of Langerhans
(72).
Basal amounts of glucagon are essential for maintenance of
normog1ycemia and to prevent hypoglycemia (73)* Glucagon's role in
glucose homeostasis is crucially dependent on the simultaneously
occurring changes in insulin concentration. Since the actions of
insulin and glucagon oppose each other, they must be viewed in 
relation to each other in all metabolic symptoms (7*0-
Glucagon promotes the hepatic uptake of glucogenic precursor
amino acids and increases intrahepatic shunting of alanine into
gluconeogenic pathways (75). Normally, enhanced g1uconeogenesis
diminishes after about a week's starvation (78). As emphasized
earlier in the discussion, glucagon also has been recognized as an
important regulatory hormone in the ketogenic process.
Description of the Protein Sparing Modified Fast
In an effort to minimize the breakdown of lean muscle mass
that accompanies starvation, the PSMF was developed. B1ackburn et a 1.
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(77) postulated that protein sparing occurred because of a decrease in
serum glucose and insulin concentration, which permitted greater endo­
genous fat mobilization and utilization. In support of this hypothesis,
they noted an inverse correlation between plasma glucose and insulin
concentration and nitrogen sparing. In addition, nitrogen sparing and
plasma concentrations of FFA and ketone bodies were positively corre­
lated. As a result they recommended the avoidance of glucose-containing
solutions.
Weight reduction with a PSMF is associated with a maintenance
of total body protein turnover parameters and nitrogen balance but a 
reduction in skeletal protein breakdown (78). The metabolic adapta­
tion which occurs during total fasting and results in reduced weight
loss develops in the course of a PSMF. After a deficit in lean body
mass is produced, net protein anabolism can be achieved by a PSMF
despite insufficient dietary energy (79).
Since follow-up reports have established that supplemented 
fasting does not of itself alter eating habits (80), the proponents 
of the PSMF recommend that it be only one aspect of a comprehensive
weight control program. Other areas of emphasis may include exercise 
(81), nutrition education and behavior modification (82). The rapid
weight loss that is achieved with the PSMF does appear to be a 
strong motivator (83) and reinforces the components of education and
behavior modification.
The obese person demonstrates response to external cues and
nonphysiologic stimuli in the eating process, in contrast to the
15
non-obese individual whose caloric intake is affected more by the 
internal hunger-satiety cues (84). 
avoidance (85) are essential and significant aspects of the program.
Contradindicat ions (86) to admission in the program include 
those individuals with juveni1 e-type diabetes, since insulin therapy
With the PSMF, cue control and
cannot be withdrawn. Patients in whom protein intakes must be limited
such as those with severe liver and renal disease and individuals who
have recently experienced a myocardial infarction should not be allowed
to participate in the PSMF. For the patient with marginally compen­
sated cerebrovascular and cardiovascular disease, care must be taken
to individualize the therapy.
The PSMF should be restricted to persons who are at least 30
percent over desirable body weight (87). Studies (88) have shown
that non-obese individuals cannot conserve body protein well on
hypocaloric diets and might lose more nitrogen than is clinically 
desirable. Therefore, it is recommended that the PSMF only be indi­
cated for patients with severe or moderate obesity. Bistrian (89) 
feels that the markedly obese person whose weight exceeds 200 percent 
ideal body weight (IBW) is resistant to balanced deficit dieting and 
his ability to maintain body weight is minimal. Although, the PSMF
may be used by the morbidly obese person with short-term goals such 
as in preparation for surgery or in medical emergencies like the
Pickwickian Syndrome.
A thorough medical history and physical should be completed
on each individual before beginning the modified fast and the
16
following baseline data obtained: ECG, chest x-ray, thyroid function 
test, CBC, random glucose, blood chemistry profile and electrolytes
including CO2 and uric acid (90). 
clinic serve as important reinforcing agents in the program and help 
maintain patient compliance (91).
Weekly visits to the outpatient
Weight, blood pressure and urinary 
ketone levels are measured every week, in addition to random glucose, 
electrolytes, CO2 and uric acid on a biweekly basis, and CBC and blood 
chemistry profile monthly (92).
In 197^ Blackburn et al. (93) investigated the biochemical
and clinical aspects of the PSMF while following 146 patients at the
Massachusetts Institute of Technology Clinical Research Center. They
found that males could maintain nitrogen balance with 1.4 gm protein/
day/kg IBW and females needed 1.2 gm/kg IBW.
The protein used must be of high biological value such as
that found in animal sources (94), and originally protein was the
sole nutrient contained in the formula. Daily intakes have included
30-55 gm of casein (95), 25 to 45 gm of egg albumin (96), or 1.1 to
1.4 gm of protein/kg IBW in the form of lean mean, fish or fowl (97).
Carbohydrate in the form of mono- or oligosaccharides has been
added to the protein in the amount of 20 to 80 gms (98, 99). Tota 1
caloric intake ranges from 300 to 800 calories/day on the various
programs (100). The supplement is ingested in three to five spaced
portions throughout the day with a fluid intake of at least 2000 ml
(101).
The protein-sparing nature of this diet regimen increases 
potassium requirements and therefore supplementation is crucial (102).
17
Two grams of potassium per day, with half provided by the protein
source, and the other half from an oral supplement, will maintain
potassium balance (103). Any liquid form of potassium may be used,
although potassium chloride in slow-release tablets is not advised
because of reduced gut motility in semi-starved patients (104). Salt
intake of at least 5 gms/day is desirable because of the obligate
naturesis of fasting (104. Vitamin and mineral supplements provid­
ing 100 percent of the daily requirements should also be administered
(106).
The PSMF is characterized by a fall in serum insulin and
glucose concentrations, and a rise in glucagon, free fatty acid and 
ketone levels (107). Other physiological changes which occur include
a temporary fall in total protein, albumin, polymorphonuclear leuko­
cytes and total white blood cell counts, but the levels remain within
normal adult ranges (108). Cel 1-mediated immunity also remains nor­
mal as do hemoglobin and hematocrit values (109). 
tion is also associated with a gradual fall in T^ 
in reverse T^ levels (110). 
triglycerides (111).
Dietary restric-
levels and a rise
There is a fall in serum cholesterol and
Naturesis, kaluresis and diuresis is exhibited during the PSMF
(112). Through initiation of a sodium diuresis hypertensive patients
experience a benefit and in general tolerate a withdrawal of hyper- 
tens i ve drugs (113). Patients who are only minimally obese have the 
highest serum ketone levels and are also the most likely to experience 
the signs and symptoms of postural hypotension and electrolyte
18
disturbances in the early phase of modified fasting (114).
Serum uric acid levels rise initially but return to normal
within a few months (115). An important difference between PSMF and
total fasting is the greater elevation of serum uric acid in total
fasting, presumably due to less competition for excretion with
ketone bodies, since plasma ketone body concentrations are lower in
PSMF (116) .
The nitrogen sparing of a PSMF persists during infection,
therefore the development of mild intercurrent illness need not
interfere with continuation of the PSMF (117). The typical amount
of fat lost during the PSMF is 0.66 pounds (0.3 kg/day) for males and 
0.44 pounds (0.2 kg/day) for females (118, 119) with nitrogen balance
maintained, suggesting nearly complete preservation of lean body
Plateauing of weight loss does not occur for periods longer 
than several days (120).
mass.
Common side effects during the PSMF include transient initial
diarrhea, fatigue, dizziness, muscle cramps, dry skin (121), tempo­
rary hair loss (122) and amenorrhea (123). Constipation is minimized
by increased fluid intake and bulk producing agents such as bran and 
mild laxatives (124). Complaints of cold intolerance, indicating 
functional hypothyroidism, are common but symptoms are usually mild
(125) . Those with exceptionally large amounts of weight loss may
experience a sense of confusion or disorientation with regard to self-
Respiratory function (12/) and exer­
cise tolerance (128) show improvement as a result of weight loss.
identity and body image (126).
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Controversy regarding the PSMF and other semi starvation regi­
mens has developed in relation to the liquid protein diet. Liquid
protein contains only small amounts of potassium, phosphorus and mag-
nesiurn. Thus three of the essential nutrients for maintenance of
lean tissue--nitrogen, potassium and phosphorus (l29)--are inadequate
in either quantity or quality. Potassium deficiency is of particular
concern given the presumed cardiac nature of the unexplained deaths 
attributed to the liquid protein diet (130) and the extensive evidence
in animals linking potassium depletion to myocardial degeneration
(131).
Contaldo explains the sudden deaths which occurred during the
liquid protein diets in relationship to the potential toxicity in the
myocardium of the low biological-va1ue proteins used, hydrolysed col­
lagen or gelatin and their deficit of branched-chain amino acids (BCAA) 
(132) or of some minerals, such as cadmium (133) or selenium (13*0
which play a physiological role in myocardium contractility, 
ficiency of electrolyte supplements including potassium, magnesium and 
calcium is further aggravated by the pronounced negative nitrogen 
balance expected with this type of diet.
The insuf-
The use of high biological 
value proteins and adequate electrolyte supplements minimize the risk
of employing extreme energy deprivation in the treatment of severe
obesity (135). There is also the likelihood that unrelated deaths
will occur at some time in this high risk population (135).
Recently, cases of seventeen individuals who died suddenly
after prolonged use of low calorie formula diet, were reviewed (137)-
20
Electrocardiograms and pathological specimens revealed a pattern of
cardiac changes. The deaths appeared to be independent of medical
supervision, vitamin and mineral supplementation and the biological
quality of the protein used. The authors recommended that the PSMF
be curtailed until further studies determine the safety.
There are few absolute known contraindications to medications
while consuming a PSMF, the most significant being diuretic drug
therapy (138). The diuretic effect of the PSMF acts synergistica11y
with such medications, and notable postural hypotension can occur 
along with serious potassium depletion. Other antihypertensive drugs
may be continued along with the monitor of blood pressure response.
Patients with gout taking allopurinol may continue the medication
(139). Precipitation of gout by PSMF is rare.
The Refeeding Stage
The refeeding stage (140) should involve a four- to six-
week period to minimize an abrupt weight gain which can result from
the antidiuresis induced by dietary carbohydrate. Simple sugars
should especially be avoided, so as not to aggravate this problem.
It is suggested that the patient begin the refeeding with the addition 
of low carbohydrate vegetables (3 percent to 6 percent CHO) and skim
milk, then progress to higher carbohydrate containing vegetables,
fruits and cereals. Potassium supplementation may be discontinued
in the refeeding stage, and after ketonuria disappears. Vitamin sup­
plements, however, should be continued.
As a result of weight reduction and a hypocaloric diet, a
21
decrease in basal metabolic rate will exist (141). Therefore, an esti­
mate of caloric needs must be a conservative one so as not to lead to
weight gain during this phase. Obviously a return to former inappro­
priate eating habits may also cause a weight gain.
The short-term effectiveness of modified fasting has been
confirmed (142) . One follow-up study after two years indicated more
than 50 percent of the initial weight loss was maintained in 40 percent 
of the patients (143). This is markedly better than weight maintenance
after calorie-deficit dieting (144).
Modified fasting has been continued for long periods without 
apparent untoward effects (145) as evidenced by one patient who fasted
for 92 weeks (1 year, 8 months) (146). Intermittent supplemental
fasting has also been suggested as an alternative for maintenance (147).
For example, Stockholm suggests a program combining the PSMF (8 weeks)
with alternating 3-week periods of a conventional diet (900 - 1200 cal)
(148). 1) to recuperate any loss 
of lean body mass which may have occurred, and 2) to introduce a
This regimen has a twofold purpose:
design that patients might realistically adhere to indefinitely.
A study (149) comprised of 207 morbidly obese patients was
submitted to the PSMF for a period of less than one month to more
than two months. Analysis revealed that the patients with onset of
obesity in childhood had the lowest tolerance for fasting and the
lowest success rate in attaining normal weight. Follow-up showed
that regain to original weight occurred in 50 percent within two to
three years and only seven patients remained at their new weights.
22
Regain to greater than original weight was more common in childhood
onset obesity than adult onset.
Treatment of Diabetes Mellitus with the PSMF
The beneficial effects of total fasting on carbohydrate
metabolism and diabetic patients were known even before the discovery
of insulin (150). Many investigators since then have documented the
improvement following weight reduction in diabetes mellitus, carbo­
hydrate tolerance and hyperinsulinism (151). Starvation and semi­
starvation liberates insulin receptor sites making endogenous insulin 
effective in controlling blood sugar (152).
In a study done by Bistrian et a 1. (153) a PSMF was applied
to obese adult-onset diabetics who were receiving 30 to 100 units of
insulin per day. As a result of this treatment insulin could be
discontinued after 0 to 19 days with preservation of lean body mass.
Treatment of Childhood Obesity with the PSMF
The implications of childhood onset obesity are particularly
disturbing, and treatment options are controversial. The impact of a
chronic negative nitrogen balance on lean body mass can be extensive,
as has been discussed. In children, these changes due to balanced
deficit dieting when protein intakes are too low are highlighted by
a reduction in the rate of height increase in addition to the negative 
nitrogen balance (15*0. In some pediatric patients, especially those
without massive fat stores, lower concentrations of insulin (as com­
pared to adult patients) may insufficiently retard proteolysis or
23
stimulate protein synthesis, such that net nitrogen balance is nega­
tive and a higher proportion of lean tissue is catabolized (155).
A group of children who were treated for more than six months
with a calorie deficit diet showed decreased growth rates (155),
although it is thought that short-term semi-starvation with 600 to
800 calories/day may not delay growth (157). Eight pediatric patients
who remained on the PSMF for one to five months were given follow-up
examinations at six months which revealed no change in height for
age (158). Thus, Merritt (159) feels that short-term semi-starvation
may result in more weight loss and less depression of growth than
prolonged calorie-deficit dieting in pediatric patients.
Pencharz (160) also assessed the effect of an energy restricted,
adequate protein diet on the nitrogen metabolism of obese adolescents.
He concluded that exogenous energy restriction in obese adolescents
does not interfere with their whole-body protein turnover provided
that they receive an adequate protein intake. In a hypocaloric diet
particular attention must be paid to the aspect of hunger.
lescents with the Prader-Willi syndrome (exhibiting nonfunctioning
*
satiety center of the hypothalamus) received a PSMF (161).
Four ado-
Given the
mental retardation and failure of the satiety characteristics of the
syndrome to develop, it was surprising to note that hunger was elimi­
nated or at least reduced by modified protein-sparing fasting (162).
Composition of the Formula Used in the PSMF
After discussion of the physiological and biochemical changes
in the semi-starved individual, it is now important to consider the
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protein-sparing ability of different nutrients--carbohydrate, protein
and fat--and also their effects on ketogenesis and the hormonal milieu.
Wolfe (163) observed that glucagon secretion was stimulated by
amino acid infusion, and that the addition of glucose dampened the
glucagon stimulation. Ketosis, seen with infusion of amino acid
alone, was largely prevented by addition of glucose to the infusion
(164). Greenberg and Jeejeebhoy (165) confirmed the theory that
positive nitrogen balance can be achieved by peripheral infusions of
amino acids without additional nutrients but there was a noted de­
crease in the concentration of circulating ketone bodies when a higher 
amino acid dosage was provided (O.83 or 1.83 gm amino acid/kg IBW/day).
The energy derived by mobilization of endogenous fat reserves con­
tributed 84 percent of the patient's energy needs when the lower
amino acid dose was employed, as compared to Jk percent on the higher
amino acid dose.
Another study (166) showed that the addition of hypocaloric
dextrose or hypocaloric intralipid was not effective in improving the
protein sparing effect achieved by peripheral infusion of 1 gm amino
acid/kg IBW/day. Shizgal compared a 5 percent casein hydrolysate
solution to a 5 percent glucose solution and found that in the patients
receiving protein, the loss of body weight resulted entirely from a
loss of body fat as contrasted to the patients receiving glucose in 
whom half of the weight loss came from lean body mass (I67).
Howard observed the response of ten patients to a regimen
involving the addition of glucose to an amino acid solution. 11 had
25
the expected effect of increased glucose and insulin levels and
decreased serum fatty acids and ketones, but the added glucose de­
creased the net protein breakdown as reflected by a small to moderate
decrease in nitrogen excretion. Nitrogen balance was significantly
more positive during the period when the subjects received glucose 
plus amino acids (168). It is felt that the decrease in net protein
breakdown effected by glucose is quantitatively more important than
any catabolic effect engendered by glucose induced suppression of
lipolysis and ketogenesis (169).
In another study (170), seven obese subjects were placed on 
400 calorie protein diet and on an isocaloric mixed diet (50 percent 
protein and 50 percent CHO) for three to five-and~a-ha1f weeks for
each diet. Despite the two-fold to five-fold increases in ketone
levels in the blood and urine with the protein diet, net nitrogen
balance was no different from that with the mixed diet. Although
there was a greater sodium depletion, a decrease in sympathetic ner­
vous system activity and development or orthostatic hypotension with
the protein diets.
In Wolfe's studies (171), although the infusions were not
isocaloric, he found that the amino acids resulted in an elevation
of glucagon levels even in the presence of other substrates. The
caloric supplementation that produced the greatest degree of nitrogen
economy was usually associated with high insulin and low glucagon
and an elevation of the insulin to glucagon ratio.
With the addition of carbohydrate to the formula various
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1) the ketogenic response is blunted (172) andresponses occur:
reduced ketosis may reinstate hunger (173), 2) suppression of gluco- 
neogenesis is due to increased insulin levels (17*0, and 3) increased
fluid retention may limit improvement in respiratory function (175).
Severe carbohydrate restriction has been found to cause
increased accumulation of plasma BCAA after a protein feeding, whereas
hypocaloric pure carbohydrate refeeding restores BCAA responses to
norma 1 (176). It appears that glucose administration produces a re­
duction in the levels of most circulating amino acids (except alanine 
and glycine) and especially the BCAA, an effect not produced by equi- 
calorific amounts of fat (177). This reduction in amino acids is due
primarily to glucose stimulated insulin release, which causes marked
amino acid uptake by muscle cells (178). Amino nitrogen thus is less
available to liver for urea cycle enzymes and less urea is synthesized.
In addition, insulin also suppresses ureogenesis independent of
an effect on amino acid supply to the liver (179). It is suggested
that the mechanism of nitrogen conservation after high dose carbohy­
drate is related primarily to substrate availability and insulin
induced diminution of amino acid release from muscle protein and 
subsequently diminished ureogenesis (180).
Wolfe conducted extensive studies and found that both in
starvation and with infused amino acids improved nitrogen economy
was readily achieved when glucose was given. Glucose at low dose
favored protein synthesis and lowered ketones, but produced no change
in the level of plasma insulin or glucagon. The non-protein substrates
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administered with amino acids improved nitrogen economy in the follow­
ing order: glycerol, low dose glucose, fat emulsion and high dose
glucose. The accompanying endocrine and biochemical changes suggest
the milieu for ideal utilization of infused amino acids: ketones at
low range (as observed with carbohydrate feeding) or moderately ele­
vated (with fat emulsion) (l8l). Although, other studies have shown
that fat infusion did not affect nitrogen excretion at any level of
carbohydrate intake (182).
The quantitative effect on protein utilization of an isoener-
getic exchange of dietary fat for carbohydrate was studied in ten
The diet consisted of milk protein (0.57 gm/kg 
body weight/day) with two ratios of carbohydrate to fat calories: 
diet A supplied an equal proportion of energy from carbohydrate and 
from fat, and diet B supplied twice as much energy from carbohydrate
healthy, young men.
as from fat. Nitrogen balance and dietary protein utilization were
significantly improved on diet B. Additional carbohydrate in diet B
resulted in significant reduction in fasting serum urea nitrogen, total
urinary nitrogen and urinary urea nitrogen; fasting plasma insulin 
values were unchanged (I83).
Therefore, it seems that many investigators agree that carbo­
hydrate has a progressive nitrogen-sparing effect. The reduction in
nitrogen excretion is due to increased tissue protein synthesis from
available amino acids or reduced breakdown (184). Carbohydrate spares
as much body nitrogen as has been reported for an amino acid regimen
and is cheaper than amino acids.
METHODS
Subj ects
A total of 18 healthy, obese adults (15 women and three men)
ranging in age from 23 to 65 years were studied. The subjects were
19 to 88 percent above ideal body weight (according to Metropolitan 
Life Insurance Tables). All subjects were free from renal, liver and
heart disease, diabetes mellitus and gout. A medical history question­
naire and blood chemistry profile for each individual were reviewed by
the team physician. Subjects were interviewed by the researchers
regarding nutritional history and habits. These volunteers were
informed of the nature, purpose, and possible risks of the study before
obtaining their written voluntary consent to participate.
Di ets
The study was designed to include two independent, one-week
modified fasting periods which were scheduled four weeks apart. The
formula provided A00 calories per day and consisted of a high biologi­
cal value protein (dried egg white) and a carbohydrate source (either
corn starch or glucose) (see Table 1). Subjects were also provided
multivitamin supplements, broth and Ensure flavor packets. 11 was
felt that the supplementation of potassium would not be necessary due
to the relatively short modified fasting period. Adequate amounts of 
fluid were encouraged in the form of noncaloric beverages. During
the modified fasting periods, subjects were contacted by telephone 









Ca rbohyd ra te 
Source
75% 25% Corn Starch
75 25 G1ucose
25 75 Corn Starch
IV 25 75 G1ucose
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Ana 1yses
Blood samples were obtained during the post-absorptive state
after an eight-hour fast on the day before initiation of the formula
diet and on the final modified fasting day.
For the glucagon determination, a 5 ml blood sample was col­
lected in a chilled EDTA tube with 0.5 ml Trasylol immediately added
After centrifuging at 4° C the cold plasmato prevent proteolysis.
was transferred to plastic tubes and stored at -20°C. The glucagon assay
was performed in duplicate using the Radioassay Systems Laboratories,
Inc. standard procedure for the radioimmunoassay of human plasma glu- 
The results are expressed as pi cograms glucagon per ml serum. 
Samples for insulin analysis were obtained in 10 ml vacutainers, allowed
cagon.
to clot and the serum collected and stored at -20°C. The Becton Dickin­
son radioimmunoassay technique was used for the quantitative determina­
tion of serum insulin levels. Insulin values are reported in micro
units insulin per ml serum.
RESULTS AND DISCUSSION
The hypocaloric diets used in this study varied in composition 
in relationship to l) percent calories as protein, 2) percent calories 
as carbohydrate, and 3) carbohydrate source—corn starch or glucose.
The number of subjects in the different groups varied due to subject
dropout and accidental loss of samples.
Table 2 lists baseline and post-fast average glucagon values
for each diet group during both periods. There was no significant
difference in the post-fast glucagon values relative to baseline data
among the diet groups. Although, during Period 2 the glucagon response
exhibited a trend of increasing values at the end of the modified fast­
ing period.
Analysis of insulin values (see Table 3) revealed no signifi­
cant changes with respect to the four diet groups during the two periods.
An expected decrease in insulin was exhibited by most groups.
An interpretation of the evaluation of the insulin to glucagon 
ratios, as listed in Table k, showed no significant differences among
the diet groups. Once again though, the post-fast values did exhibit
a downward trend.
Diets III and IV (containing 75 percent carbohydrate) were
expected to have induced a significantly greater rise in insulin and
Wolfe (185) foundthus an increase in the insulin:glucagon ratio.
that the greatest amount of nitrogen sparing occurred as a result of
this high hormonal ratio. Conversely, a more recent study showed no





Baseline Glucagon, pg/ml 
Std. Dev.
Post-Glucagon, pg/ml 
Mean Std. Dev.PSMF Period I Mean n
44.76 (+ 10.31*)Diet I 41.89 (+ 9.32) 3
61 .02 (+ 9.39)Diet II 53.08 (+ 14.04) 6
44.02 (+ 0.00)Diet I I I 55-02 (+ 0.00) 1
72.26 (+ 10.y1!)Diet !V 70.50 (+ 16.01) 6
PSMF Period I 1
(+ 6.31)Diet I 53.77 61.11 (+ 14.92) 2
67.92Diet II (+ 13.29) 81.21 (+ 11.61) 3
37.80 (+ 15.73)Diet I I I 1)7.10 (+ 6.70) 2
69.31Diet IV (+ 13.89) 66.67 (+ 10.10) 3




Baseline Insulin, uU/ml 
Mean Std. Dev.
Post-Insulin, uU/ml 
Mean Std. Dev.PSMF Period I n
14.57 (+ 4.26) (+ 0.13)Diet I 13.11 2
(+ 2.28)Diet II (+ 3.12)21.12 613-30
(+ 4.48)12.44Diet III (+ 2.23)13.51 2
18.21 (+ 2.95)Diet IV (+ 3.70)12.72 5
PSMF Period I I
9.56 (+ 1.42)Diet I (+ 0.57)7.25 2
(+ 3.49)Diet I I (+ 13.65)29.9620.72 2
Diet I I I (+ 6.56)12.91 13.65 (+ 1.60) 2
16.55 (+ 2.84)Diet IV (+ 8.56)13.29 2






Pos t-Ra tio 
Mean Std. Dev.PSMF Period I Std. Dev. n
(+ 3.27)8.86 (+ 1.38)8.33Diet I 2
(+ 1.56)8.23Diet I I 6.00 (+ 1.48) 6
(+ 0.00)4.91 (+ 0.00)Diet I I I 5.06
(+ 1.14)5.98 4.28 (+ 1.65)Diet IV 5
PSMF Period I I
4.21Diet I (+ l.H) (+ 0.49)2.77 2
(+ 1.90)6.59 (+ 5.53)Diet II 9.57 2
7.80 (+ 0.80) (+ 1.77)Diet III 6.89 2
6.25 (+ 2.57) (+ 2.84)4.30Diet IV 2
p value - n.s.
* Calculated as: Insulin, uU/ml x 23-33
Glucagon, pg/ml
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feeding (186). The conclusion was that the protein-sparing influence
of protein feeding cannot be ascribed to the decline in insulin secre­
tion.
In reference to the ketogenic model which McGarry (187) pur­
ports, an increased glucagon response causes greater fat mobilization
and subsequently ketone body formation. It appears that the high
protein diet elicits higher ketone body levels although this is not
always consistent with rises in glucagon (188). The results of this
study concurred with DeHaven and others in that no significant change
was observed after the high or low protein diet. Diets I I and IV which
contained glucose did have a higher acceptance level and smaller attri­
tion rate than those which contained the corn starch.
The weight loss at the end of either seven-day modified fasting
period ranged from one pound to 16 pounds with a mean of 7-5 pounds
(see Tab 1e 5). At the end of the eight-week comprehensive program the




Weight Loss Resulting from PSMF
Period I 
Mean Lbs.
Period I I 
Mean Lbs.Diet n n
6.1I 3 3.5 2
6I I 11.3 5.5 3
6.5I I I 2 2.5 2
6IV 7.3 12.5 3
SUMMARY
A total of 18 obese men and women volunteered and participated
in a seven-day protein sparing modified fast providing 400 calories per
day. The subjects were concurrently participating in an eight-week
weight control program combining the facets of nutrition education,
group therapy, and values clarification. The modified fast, which was
optional, was conducted during two different time periods with a con­
ventional low calorie diet prescribed during the four-week interval.
The diet formula consisted of a high biological value protein,
dried egg white, and either glucose or corn starch as the carbohydrate
The composition of the diets varied as follows: Diet I - 75%source.
protein, 25% corn starch; Diet II - 75% protein, 25% glucose; Diet 
III - 25% protein, 75% corn starch; Diet IV - 25% protein, 75% glucose. 
The hormonal response of glucagon and insulin relative to the four
diets was evaluated. Baseline and post-fast serum samples were ob­
tained from the subjects.
Analysis showed no significant difference in response elicited
by the various diets of either insulin or glucagon or in the insulin
to glucagon ratio. The mean weight loss during both modified fasting
periods was 7*5 pounds with a range of one pound to 16 pounds. The
total weight loss for an individual at the end of the eight-week
program ranged from three pounds to 27 pounds with a mean of 13*7
pounds.
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48.9201 2 51.843 17.55 12.52
03 26.682 42.363 08.27 14.78
04 4 76.052 14.43 19.3471.53

















08 4 78.552 55.05 * *
49-3111 2 1 07.6557.33 10.57
81.1012 83.732 18.252 20.30
68.1415 68.542 2 39.6123.19
17 54.532 2 91.35 * *
18 58.232 65.911 08.55 06.85
* Data not available.
